Lawrence Nogee’s clinical and research interests are in lung diseases in newborns as well as older children, with a particular focus on genetic lung diseases. His laboratory research focuses on identifying genetic mechanisms leading to neonatal respiratory failure and diffuse and interstitial lung diseases in older infants and children. This includes understanding the biology, molecular epidemiology and pathophysiology of lung diseases due to genetic surfactant dysfunction through molecular and genetic analyses of samples from individuals with these rare lung disorders.
In addition, his laboratory actively seeks to identify novel genetic causes of childhood interstitial lung disorders, determine the role of genetic variants in surfactant-related genes in contributing to more common neonatal lung diseases, and use the study of these disorders to improve our understanding of normal surfactant metabolism. Long-term goals include translating basic science findings into improved diagnostic tests for rare neonatal and diffuse lung disease, and developing more effective therapies for these disorders, and he is part of a multicenter collaboration to develop specific therapy for ABCA3 deficiency, the most common cause of genetic surfactant dysfunction.
Dr. Nogee is an active participant in the Children’s Interstitial Lung Disease Research Network (ChILDRN) and part of the Johns Hopkins Center for Pulmonary Hypertension and Congenital Diaphragmatic Hernia working groups, is a site co-investigator on a multicenter trial of treprostinil as add-on therapy for persistent pulmonary hypertension of the newborn, and a co-investigator on the NIH-funded trial evaluating serial amnioinfusions to rescue the lethal pulmonary hypoplasia associated with early-onset anhydramnios (PI: Eric Jelin, general pediatric surgery).
Learn more about clinical trials at Johns Hopkins Medicine.
Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, Hamvas A, Nogee LM. “Genotype-phenotype correlations for infants and children with ABCA3 deficiency.” Am J Respir Crit Care Med. 2014 Jun 15;189(12):1538-43. doi: 10.1164/rccm.201402-0342OC. PubMed PMID: 24871971; PubMed Central PMCID: PMC4226019.
Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, Dell S, Fan LL, Hamvas A, Hilman BC, Langston C, Nogee LM, Redding GJ; American Thoracic Society Committee on Childhood Interstitial Lung Disease (chILD) and the chILD Research Network. “An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.” Am J Respir Crit Care Med. 2013 Aug 1;188(3):376-94. doi: 10.1164/rccm.201305-0923ST. Review. PubMed PMID: 23905526; PubMed Central PMCID: PMC3778735.
Nogee, LM and Hamvas, A. The Past and Future of Genetics in Pulmonary Medicine – You Can Teach an Old Dog New Tricks. Pediatr Pulmonol, 55:1789-1793, 2020. PMID: 32533910
Wambach, JA and Nogee, LM. A step towards treating a lethal neonatal lung disease: STAT3 and alveolar capillary dysplasia. Am J Resp Crit Care Med, 200:961-2, 2019.
Nogee, LM. Genetic Causes of Surfactant Protein Abnormalities. Curr Opin Pediatrics, 31:330-9,2019.